Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer’s disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta...